Aliases & Classifications for Cholera

MalaCards integrated aliases for Cholera:

Name: Cholera 12 72 49 55 51 40 3 41 14 69
Cholera Due to Vibrio Cholerae 12
Cholera - Vibrio Cholerae 12
Vibrio Cholerae Infection 49

Characteristics:

Orphanet epidemiological data:

55
cholera
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),<1/1000000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1498
ICD9CM 34 001 001.0 001.9
MeSH 41 D002771
Orphanet 55 ORPHA173
MESH via Orphanet 42 D002771
UMLS via Orphanet 70 C0008354
ICD10 via Orphanet 33 A00.0 A00.1 A00.9
UMLS 69 C0008354

Summaries for Cholera

MedlinePlus : 40 Cholera is a bacterial infection that causes diarrhea. The cholera bacterium is usually found in water or food that has been contaminated by feces (poop). Cholera is rare in the US. You may get it if you travel to parts of the world with poor water and sewage treatment. Outbreaks can also happen after disasters. The disease is not likely to spread directly from person to person. Cholera infections are often mild. Some people don't have any symptoms. If you do get symptoms, they usually start 2 to 3 days after infection. The most common symptom is watery diarrhea. In some cases, the infection can be severe, causing lots of watery diarrhea, vomiting, and leg cramps. Because you quickly lose body fluids, you are at risk for dehydration and shock. Without treatment, you could die within hours. If you think that you might have cholera, you should get medical care right away. Doctors diagnose cholera with a stool sample or rectal swab. Treatment is the replacement of the fluid and salts that you lost through the diarrhea. This is usually with a rehydration solution that you drink. People with severe cases may need an I.V. to replace the fluids. Some of them may also need antibiotics. Most people who get fluid replacement right away will recover. There are vaccines to prevent cholera. One of them is available for adults in the U.S. Very few Americans need it, because most people do not visit areas that have an active cholera outbreak. There are also simple steps you can take to help to prevent cholera infection: Use only bottled or purified water for drinking, washing dishes, making ice cubes, and brushing your teeth If you do use tap water, boil it or use iodine tablets Wash your hands often with soap and clean water Make sure that the cooked food you eat is fully cooked and served hot Avoid unwashed or unpeeled raw fruits and vegetables Centers for Disease Control and Prevention

MalaCards based summary : Cholera, also known as cholera due to vibrio cholerae, is related to pancreatic cholera and gastroenteritis, and has symptoms including pruritus and fever. An important gene associated with Cholera is ARF1 (ADP Ribosylation Factor 1), and among its related pathways/superpathways are GPCR Pathway and Vesicle-mediated transport. The drugs Formaldehyde and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include skin, small intestine and eye.

NIH Rare Diseases : 49 Cholera is an infection of the small intestines that is caused by the bacterium Vibrio cholera. The condition can range from mild to severe and many affected people may have no obvious signs or symptoms. Approximately 5-10% of infected people will have severe disease with watery diarrhea and vomiting leading to rapid fluid loss, dehydration, and shock. If left untreated, this can cause acute renal failure, severe electrolyte imbalances, coma, or even death. People develop cholera when they eat food or drink water that is contaminated with Vibrio cholera. The condition occurs most often in places that lack water treatment and have poor sanitation and inadequate hygiene. Treatment aims to prevent dehydration and replace the fluids and salts that are lost through diarrhea. Last updated: 4/7/2016

Disease Ontology : 12 A primary bacterial infectious disease that is described as an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae, which is characterized by profuse watery diarrhea, vomiting, leg cramps, circulatory collapse and shock.

Wikipedia : 72 Cholera is an infection of the small intestine by some strains of the bacterium Vibrio cholerae.... more...

Related Diseases for Cholera

Diseases related to Cholera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 pancreatic cholera 12.1
2 gastroenteritis 11.4
3 secretory diarrhea 11.3
4 vipoma 11.1
5 wdha syndrome 11.1
6 pancreatitis 10.3
7 diarrhea 10.3
8 pertussis 10.2
9 mucositis 10.2
10 juvenile dermatitis herpetiformis 10.1 ADCY10 CD79A
11 shigellosis 10.1
12 aging 10.0
13 acute diarrhea 10.0
14 dysentery 10.0
15 typhoid fever 9.9
16 cholecystitis 9.9
17 neuronitis 9.9
18 glioma 9.9
19 polykaryocytosis inducer 9.9
20 cystic fibrosis 9.9
21 neuroblastoma 9.9
22 pasteurellosis 9.9
23 acalculous cholecystitis 9.9
24 plague 9.9
25 bronchitis 9.9 CD79A CFTR VIP
26 mite infestation 9.8 CD79A CFTR
27 fibrosis of extraocular muscles, congenital, 1 9.8
28 malaria 9.8
29 allergic conjunctivitis 9.8
30 conjunctivitis 9.8
31 fasciitis 9.8
32 necrotizing fasciitis 9.8
33 pancreatic cancer 9.7
34 bacteremia 2 9.7
35 malignant glioma 9.7
36 lymphoma 9.7
37 chlamydia 9.7
38 erysipelas 9.7
39 diphtheria 9.7
40 cellulitis 9.7
41 retinitis 9.7
42 pneumonia 9.7
43 influenza 9.7
44 neuropathy 9.7
45 trichinosis 9.7
46 blood group, i system 9.6
47 colorectal cancer 9.6
48 cataract 5, multiple types 9.6
49 multiple endocrine neoplasia, type i 9.6
50 medulloblastoma 9.6

Graphical network of the top 20 diseases related to Cholera:



Diseases related to Cholera

Symptoms & Phenotypes for Cholera

UMLS symptoms related to Cholera:


pruritus, fever

Drugs & Therapeutics for Cholera

Drugs for Cholera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-00-0 712
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
7 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
8 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
9 Calcineurin Inhibitors Phase 4
10 Cholera Toxin Phase 4,Phase 3,Phase 1
11 Cyclosporins Phase 4
12 Immunosuppressive Agents Phase 4
13 Methylprednisolone acetate Phase 4
14 Methylprednisolone Hemisuccinate Phase 4
15 Prednisolone acetate Phase 4
16 Prednisolone hemisuccinate Phase 4
17 Prednisolone phosphate Phase 4
18
Azithromycin Approved Phase 3 83905-01-5 53477736 447043 55185
19
Ciprofloxacin Approved, Investigational Phase 3,Phase 1 85721-33-1 2764
20
Zinc Approved, Investigational Phase 3,Phase 1,Phase 2 7440-66-6 32051 23994
21
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 1,Phase 2
24 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Phase 1
25 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 1
27 Micronutrients Phase 3,Phase 1,Phase 2
28 Trace Elements Phase 3,Phase 1,Phase 2
29 Erythromycin Estolate Phase 3
30 Erythromycin Ethylsuccinate Phase 3
31 Erythromycin stearate Phase 3
32 Acidophilus Nutraceutical Phase 3
33
Albendazole Approved, Vet_approved Phase 1, Phase 2 54965-21-8 2082
34
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
35
Secnidazole Approved Phase 1, Phase 2 3366-95-8
36 Zinc sulfate Approved, Investigational Phase 1, Phase 2 7733-02-0
37
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
38
Vitamin C Approved, Nutraceutical Phase 2,Phase 1 50-81-7 54670067 5785
39
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
40 Anthelmintics Phase 1, Phase 2
41 Antimitotic Agents Phase 1, Phase 2
42 Antiparasitic Agents Phase 1, Phase 2
43 Antiprotozoal Agents Phase 1, Phase 2
44 Astringents Phase 1, Phase 2
45 Dermatologic Agents Phase 1, Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Histamine Antagonists Phase 2
48
Histamine Phosphate Phase 2 51-74-1 65513
49 Neurotransmitter Agents Phase 2
50 Guar Nutraceutical Phase 2

Interventional clinical trials:

(show top 50) (show all 78)

# Name Status NCT ID Phase Drugs
1 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Completed NCT01949675 Phase 4
2 Evaluation of a Boosting Regimen With Oral Cholera Vaccine Completed NCT01579448 Phase 4
3 Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Completed NCT01524640 Phase 4
4 A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children Completed NCT00760825 Phase 4
5 Mucosal Response in Immunocompromised Host Completed NCT01109914 Phase 4
6 Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Completed NCT00125008 Phase 4
7 New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects Completed NCT00490932 Phase 4 Hypo-osmolar ORS
8 Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Recruiting NCT03373669 Phase 4
9 VAXCHORA Pediatric Study Recruiting NCT03220737 Phase 4
10 Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Unknown status NCT02027207 Phase 3
11 Safety and Immunogenicity of a New Formulation of Euvichol® Unknown status NCT02502331 Phase 3
12 Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea Unknown status NCT00534170 Phase 3
13 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Completed NCT02434822 Phase 3
14 Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata Completed NCT00289224 Phase 3
15 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Completed NCT01895855 Phase 3
16 Ciprofloxacin Multiple Dose for Adult Cholera Completed NCT00741052 Phase 3 Ciprofloxacin;Azithromycin
17 Zinc Supplementation in Cholera Patients Completed NCT00226616 Phase 3 Zinc
18 Single Dose Azithromycin in the Treatment of Adult Cholera Completed NCT00229944 Phase 3 Azithromycin
19 Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Completed NCT00142272 Phase 3 Ciprofloxacin
20 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Completed NCT02100631 Phase 3
21 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Completed NCT02094586 Phase 3
22 Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children. Completed NCT00324285 Phase 3 Amylase resistant starch added ORS
23 To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children Completed NCT02164110 Phase 3
24 Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children Completed NCT02556996 Phase 3
25 Improving Rotavirus Vaccine Immune Response Completed NCT01825109 Phase 3
26 A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants Completed NCT02133690 Phase 3
27 Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants Unknown status NCT00548054 Phase 2
28 Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Completed NCT02742558 Phase 2
29 Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata Completed NCT00119197 Phase 2
30 Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Completed NCT01233362 Phase 2
31 To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh Completed NCT01042951 Phase 2
32 Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Completed NCT00419133 Phase 2
33 Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Completed NCT00128011 Phase 2
34 Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Completed NCT00672308 Phase 2
35 Studies of Immune Responses to Orally Administered Vaccines in Developing Country Completed NCT01019083 Phase 1, Phase 2 Placebo;Placebo;Zinc Sulphate;Albendazole and Secnidazole
36 PXVX0200 (CVD103-HgR) vs Shanchol in Mali Completed NCT02145377 Phase 2
37 Field Application of Shanchol in Adults in Bangladesh Completed NCT01762930 Phase 2 Shanchol
38 Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults Completed NCT00741637 Phase 2
39 Slow Versus Rapid Rehydration of Severely Malnourished Children Completed NCT02216708 Phase 2
40 Therapeutic Induction of Endogenous Antibiotics Completed NCT00800930 Phase 2
41 Modified ORS Solution for Severely Malnourished Children Completed NCT01821586 Phase 2
42 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Active, not recruiting NCT03251495 Phase 2 Vaxchora
43 Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Active, not recruiting NCT02823899 Phase 1, Phase 2
44 Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis Terminated NCT00751933 Phase 2
45 Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Terminated NCT00624975 Phase 2
46 Efficacy of iOWH032 in Dehydrating Cholera Withdrawn NCT02111304 Phase 2 iOWH032
47 Oral Rehydration Therapy in Burn Patients Unknown status NCT02124265 Phase 1 CeraLyte 90
48 Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules) Completed NCT03237663 Phase 1
49 Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Completed NCT01585181 Phase 1
50 To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men Completed NCT01707537 Phase 1

Search NIH Clinical Center for Cholera

Cochrane evidence based reviews: cholera

Genetic Tests for Cholera

Anatomical Context for Cholera

MalaCards organs/tissues related to Cholera:

38
Skin, Small Intestine, Eye, T Cells, B Cells, Testes, Monocytes

Publications for Cholera

Articles related to Cholera:

(show top 50) (show all 969)
# Title Authors Year
1
Dynamics of Cholera Epidemics with Impulsive Vaccination and Disinfection. ( 29425779 )
2018
2
Cholera toxin enhances IL-17A production in both CD4<sup>+</sup>and CD8<sup>+</sup>cells via a cAMP/PKA-mediated IL-17A promoter activation. ( 29377102 )
2018
3
Long-run effects of early childhood exposure to cholera on final height: Evidence from industrializing Japan. ( 29349274 )
2018
4
GM1 ganglioside-independent intoxication by Cholera toxin. ( 29432456 )
2018
5
Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia. ( 29414267 )
2018
6
Surface Chemistry and Spectroscopic Study of a Cholera Toxin B Langmuir Monolayer. ( 29378405 )
2018
7
Characterization of highly virulent multidrug resistant Vibrio cholerae isolated from a large cholera outbreak in Ghana. ( 29347965 )
2018
8
Highly affine and selective aptamers against cholera toxin as capture elements in magnetic bead-based sandwich ELAA. ( 29408200 )
2018
9
Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate. ( 29434590 )
2018
10
Fucosylated molecules competitively interfere with cholera toxin binding to host cells. ( 29411974 )
2018
11
Use of cholera vaccines expands, raising hopes. ( 29439220 )
2018
12
Temporo-spatial dynamics and behavioural patterns of 2012 cholera epidemic in the African mega-city of Conakry, Guinea. ( 29448965 )
2018
13
Uptake and intracellular fate of cholera toxin subunit b-modified mesoporous silica nanoparticle-supported lipid bilayers (aka protocells) in motoneurons. ( 29339186 )
2018
14
Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. ( 29317118 )
2018
15
Spatial and population drivers of persistent cholera transmission in rural Bangladesh: Implications for vaccine and intervention targeting. ( 29413709 )
2018
16
Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia. ( 29403111 )
2018
17
Immunochromatographic detection of the heat-labile enterotoxin of enterotoxigenic Escherichia coli with cross-detection of cholera toxin. ( 27940044 )
2017
18
Comparative Analysis of Pasteurella multocida Isolates from Acute and Chronic Fowl Cholera Cases in Hungary During the Period 2005 Through 2010. ( 29337626 )
2017
19
Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines. ( 28910563 )
2017
20
IncA/C plasmids conferring high azithromycin resistance in vibrio cholera. ( 28919196 )
2017
21
Ensuring access to oral cholera vaccine to those who need them most. ( 27916414 )
2017
22
Passive, health center-based assessment of adverse events following oral cholera immunization in Nampula city, Mozambique. ( 28899627 )
2017
23
Deficiency in Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin. ( 28951732 )
2017
24
Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. ( 27916412 )
2017
25
Cholera Vaccine Use Is Associated with a Reduced Risk of Death in Patients with Colorectal Cancer: A Population-based Study. ( 28923497 )
2017
26
Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015. ( 27983502 )
2017
27
Hetero-multivalent binding of cholera toxin subunit B with glycolipid mixtures. ( 28946063 )
2017
28
Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera. ( 28319200 )
2017
29
Affinity capillary electrophoresis for the assessment of binding affinity of carbohydrate-based cholera toxin inhibitors. ( 28905402 )
2017
30
Epistemological rehabilitation of "shoe leather" epidemiology: the lesson of cholera in Haiti. ( 28861644 )
2017
31
Eliminating Cholera Transmission in Haiti. ( 27959699 )
2017
32
The role of CTX and RS1 satellite phages genomic arrangement in Vibrio cholera toxin production in two recent cholera outbreaks (2012 and 2013) in IR Iran. ( 28923607 )
2017
33
Cholera, 2016. ( 28884993 )
2017
34
Health seeking behaviour among suspected cases of cholera in Cameroonian health districts in Lake Chad basin. ( 28854951 )
2017
35
The Role of Necroptosis, Apoptosis, and Inflammation in Fowl Cholera-Associated Liver Injury in a Chicken Model. ( 29337619 )
2017
36
Sleep-inducing effect of substance P-cholera toxin A subunit in mice. ( 28866052 )
2017
37
Biology of Vibrio cholera. Editorial overview. ( 29446800 )
2017
38
H2S is a key antisecretory molecule against cholera toxin-induced diarrhoea in mice: Evidence for non-involvement of the AC/cAMP/PKA pathway and AMPK. ( 28943473 )
2017
39
Cholera - the new strike of an old foe. ( 28952662 )
2017
40
Descriptive epidemiology of a cholera outbreak in Kaduna State, Northwest Nigeria, 2014. ( 28904700 )
2017
41
Current views and challenges on clinical cholera. ( 29379258 )
2017
42
Zinc oxide nanoparticles provide anti-cholera activity by disrupting the interaction of cholera toxin with the human GM1 receptor. ( 28882894 )
2017
43
Otitis Media Caused by V. cholerae O100: A Case Report and Review of the Literature. ( 28894440 )
2017
44
Global stability and uniform persistence of the reaction-convection-diffusion cholera epidemic model. ( 27879114 )
2017
45
Development and standardization of an in-house indirect ELISA for detection of duck antibody to fowl cholera. ( 28844720 )
2017
46
Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design. ( 28916247 )
2017
47
Cost-of-illness of cholera to households and health facilities in rural Malawi. ( 28934285 )
2017
48
Cholera vaccines: WHO position paper a89 August 2017. ( 28845659 )
2017
49
Blood Group O-Dependent Cellular Responses to Cholera Toxin: Parallel Clinical and Epidemiological Links to Severe Cholera. ( 27162272 )
2016
50
AA rare case of necrotizing fasciitis caused by Vibrio cholerae O8 in an immunocompetent patient. ( 27604649 )
2016

Variations for Cholera

Expression for Cholera

Search GEO for disease gene expression data for Cholera.

Pathways for Cholera

Pathways related to Cholera according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.54 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
2
Show member pathways
13.22 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
3
Show member pathways
13.05 ADCY1 CFTR EGF GNAI1 GNAS PLCB1
4
Show member pathways
13.01 ADCY1 CD79A EGF GNAI1 GNAS PLCB1
5 12.8 ADCY1 EGF GNAI1 GNAS PLCB1
6
Show member pathways
12.73 ADCY1 GNAI1 GNAS PLCB1
7
Show member pathways
12.72 ADCY1 ADCY10 GNAI1 GNAS PLCB1
8
Show member pathways
12.65 ARF1 ARF3 ARF4 ARF5 ARL1
9
Show member pathways
12.61 ADCY1 EGF GNAI1 GNAS PLCB1
10
Show member pathways
12.58 ADCY1 ARF6 EGF GNAI1 GNAS PLCB1
11
Show member pathways
12.52 ADCY1 GNAI1 GNAS PLCB1
12
Show member pathways
12.5 ADCY1 GNAI1 GNAS PLCB1
13
Show member pathways
12.49 ADCY1 GNAI1 GNAS PLCB1
14
Show member pathways
12.44 ARF1 CFTR ERO1A GNAS
15 12.36 ARF1 ARF3 ARF5 ARF6
16
Show member pathways
12.32 ADCY1 GNAI1 GNAS PLCB1
17
Show member pathways
12.32 ADCY1 GNAI1 GNAS PLCB1
18 12.31 ADCY1 GNAI1 GNAS PLCB1
19
Show member pathways
12.19 ADCY1 ARF1 ARF6 EGF GNAS PLCB1
20
Show member pathways
12.12 ADCY1 GNAI1 GNAS PLCB1
21
Show member pathways
12.11 ADCY1 CFTR GNAI1 GNAS
22
Show member pathways
12.11 ADCY1 ADCY10 CFTR GNAI1 GNAS
23 12.02 ADCY1 GNAI1 GNAS VIP
24
Show member pathways
11.98 ADCY1 CFTR GNAI1 GNAS PLCB1
25 11.97 ADCY1 ADCY10 GNAI1 PLCB1
26 11.92 GNAI1 GNAS PLCB1
27
Show member pathways
11.91 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
28 11.89 ADCY1 GNAI1 GNAS PLCB1
29 11.85 ADCY1 EGF GNAI1 PLCB1
30 11.84 ADCY1 GNAS PLCB1
31 11.79 ADCY1 GNAI1 GNAS
32 11.76 ADCY1 CFTR GNAS PLCB1
33 11.67 ADCY1 CFTR GNAS
34 11.65 GNAI1 GNAS PLCB1
35 11.62 GNAI1 GNAS PLCB1
36 11.58 GNAI1 GNAS PLCB1
37 11.52 ADCY1 GNAI1 GNAS
38 11.5 ADCY1 EGF GNAI1 GNAS PLCB1
39 11.49 GNAI1 GNAS PLCB1
40 11.46 ADCY1 GNAI1 GNAS
41 11.41 ADCY1 GNAS PLCB1
42 11.36 ADCY1 GNAI1 GNAS PLCB1
43 11.34 ARF1 ARF5 ARF6
44 11.29 ADCY1 GNAS PLCB1
45 11.24 GNAI1 GNAS PLCB1
46 11.09 ADCY10 GNAI1 GNAS PLCB1
47 10.86 ARF1 ARF6
48 10.79 GNAI1 PLCB1
49 10.7 ADCY1 GNAI1 GNAS PLCB1

GO Terms for Cholera

Cellular components related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi apparatus GO:0005794 9.87 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
2 intracellular GO:0005622 9.65 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
3 lysosomal membrane GO:0005765 9.55 CFTR EGF GNAI1 NEU1 TRIM23
4 extracellular exosome GO:0070062 9.5 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
5 cytoplasm GO:0005737 10.21 ADCY1 ADCY10 ARF1 ARF3 ARF4 ARF5
6 plasma membrane GO:0005886 10.18 ADCY1 ADCY10 ARF1 ARF4 ARF5 ARF6
7 membrane GO:0016020 10.16 ADCY1 ADCY10 ARF1 ARF4 ARF5 ARF6

Biological processes related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vesicle-mediated transport GO:0016192 9.55 ARF1 ARF3 ARF4 ARF5 ARF6
2 retrograde vesicle-mediated transport, Golgi to ER GO:0006890 9.54 ARF3 ARF4 ARF5
3 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.5 ADCY1 GNAS VIP
4 cyclic nucleotide biosynthetic process GO:0009190 9.43 ADCY1 ADCY10
5 cAMP biosynthetic process GO:0006171 9.4 ADCY1 ADCY10
6 activation of phospholipase D activity GO:0031584 9.26 ARF4 ARL1
7 small GTPase mediated signal transduction GO:0007264 9.17 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
8 cellular response to forskolin GO:1904322 9.13 ADCY1 CFTR GNAI1

Molecular functions related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.61 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.4 GNAI1 GNAS
3 phosphorus-oxygen lyase activity GO:0016849 9.37 ADCY1 ADCY10
4 GDP binding GO:0019003 9.33 ARF1 GNAI1 TRIM23
5 adenylate cyclase activity GO:0004016 9.32 ADCY1 ADCY10
6 GTPase activity GO:0003924 9.28 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
7 guanyl nucleotide binding GO:0019001 9.26 GNAI1 GNAS

Sources for Cholera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....